Tobias Walbert
Henry Ford Health System
137 Papers
203 Citations
Tobias Walbert is an academic researcher from Henry Ford Health System. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 22, co-authored 99 publications. Previous affiliations of Tobias Walbert include Wayne State University & Ford Motor Company.
Chat about Author
Papers
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Linda M. Liau,Keyoumars Ashkan,David Tran,Jian Campian,John E. Trusheim,Charles S. Cobbs,Jason Heth,Michael Salacz,Sarah A. Taylor,Stacy D. D’Andre,Fabio M. Iwamoto,Edward J. Dropcho,Yaron A. Moshel,Kevin A. Walter,Clement Pillainayagam,Robert Aiken,Rekha Chaudhary,Samuel Goldlust,Daniela A. Bota,Paul Duic,Jai Grewal,Heinrich Elinzano,Steven A. Toms,Kevin O. Lillehei,Tom Mikkelsen,Tobias Walbert,Steven R. Abram,Andrew Brenner,Steven Brem,Matthew G. Ewend,Simon Khagi,Jana Portnow,Lyndon Kim,William G. Loudon,Reid C. Thompson,David Avigan,Karen Fink,Francois J. Geoffroy,Scott Lindhorst,Jose Lutzky,Andrew E. Sloan,Gabriele Schackert,Dietmar Krex,Hans-Jorg Meisel,Julian Wu,Raphael P. Davis,Christopher Duma,Arnold B. Etame,David Mathieu,Santosh Kesari,David Piccioni,Manfred Westphal,David S. Baskin,Pamela Z. New,Michel Lacroix,Sven-Axel May,Timothy J. Pluard,Victor Tse,Richard M. Green,John L. Villano,Michael Pearlman,Kevin Petrecca,Michael Schulder,Lynne Taylor,Anthony E. Maida,Robert M. Prins,Timothy F. Cloughesy,Paul Mulholland,Marnix L. Bosch +68 more
TL;DR: Addition of DCVax-L to standard therapy is feasible and safe in glioblastoma patients, and may extend survival, and overall adverse events withDCVax were comparable to standard Therapy alone.
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
Linda M. Liau,Keyoumars Ashkan,Steven Brem,Jian Campian,John E. Trusheim,Fabio M. Iwamoto,David Tran,George Ansstas,Charles Cobbs,Jason Heth,Michael Salacz,Stacy D. D’Andre,Robert Aiken,Yaron A. Moshel,Joo Yeon Nam,Clement Pillainayagam,Stephanie Ann Wagner,Kevin A. Walter,Rekha Chaudhary,Samuel Goldlust,Ian Lee,Daniela A. Bota,Heinrich Elinzano,Jai Grewal,Kevin O. Lillehei,Tom Mikkelsen,Tobias Walbert,Steven R. Abram,Andrew Brenner,Matthew G. Ewend,Simon Khagi,D Lovick,Jana Portnow,Lyndon Kim,William G Loudon,Nina L. Martinez,Reid C. Thompson,David Avigan,Karen Fink,Francois J. Geoffroy,Pierre Giglio,Oleg Gligich,Dietmar Krex,Scott Lindhorst,Jose Lutzky,Hans Joerg Meisel,Minou Nadji-Ohl,L. Sanchin,Andrew E. Sloan,Lynne P. Taylor,Julian K. Wu,Erin M. Dunbar,Arnold B. Etame,Santosh Kesari,David Mathieu,David Piccioni,David S. Baskin,Michel Lacroix,Sven-Axel May,Pamela New,Timothy J. Pluard,Steven A. Toms,Victor Tse,Scott Peak,John L. Villano,James Battiste,Paul Mulholland,Michael Pearlman,Kevin Petrecca,Michael Schulder,Robert M. Prins,Alton L. Boynton,Marnix L. Bosch +72 more
TL;DR: In this article , treatment with autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) was associated with improved overall survival (OS) for patients with newly diagnosed glioblastoma (nGBM) and recurrent gliomatosis (rGBM), compared with standard of care (SOC).
DNA methylation profiling to predict recurrence risk in meningioma: Development and validation of a nomogram to optimize clinical management
Farshad Nassiri,Farshad Nassiri,Yasin Mamatjan,Suganth Suppiah,Suganth Suppiah,Jetan H. Badhiwala,Sheila Mansouri,Shirin Karimi,Olli Saarela,Laila Poisson,Irina Gepfner-Tuma,Jens Schittenhelm,Ho Keung Ng,Houtan Noushmehr,Patrick N. Harter,Peter Baumgarten,Michael Weller,Matthias Preusser,Christel Herold-Mende,Marcos Tatagiba,Ghazaleh Tabatabai,Felix Sahm,Andreas von Deimling,Kenneth Aldape,Kenneth Aldape,Karolyn Au,Jill Barnhartz-Sloan,Wenya Linda Bi,Priscilla K. Brastianos,Nicholas Butowski,Carlos Gilberto Carlotti,Michael D. Cusimano,Francesco DiMeco,Katharine J. Drummond,Ian F. Dunn,Evanthia Galanis,Caterina Giannini,Roland Goldbrunner,Brent Griffith,Rintaro Hashizume,C. Oliver Hanemann,Craig Horbinski,Raymond Y. Huang,David James,Michael D. Jenkinson,Christine Jungk,Timothy J. Kaufman,Boris Krischek,Daniel H. Lachance,Christian LaFougere,Ian Lee,Jeff C. Liu,Tathiane M. Malta,Christian Mawrin,Michael W. McDermott,David G. Munoz,Arie Perry,Farhad Pirouzmand,Laila M. Poisson,Bianca Pollo,David R. Raleigh,Andrea Saladino,Thomas Santarius,Christian Schichor,David Schultz,Nils Ole Schmidt,Warren R. Selman,Andrew E. Sloan,Julian Spears,James Snyder,Daniela Pretti da Cunha Tirapelli,Joerg C. Tonn,Derek S. Tsang,Michael A. Vogelbaum,Patrick Y. Wen,Tobias Walbert,Manfred Westphal,Adriana M. Workewych,Gelareh Zadeh,Gelareh Zadeh,Gelareh Zadeh,Kenneth Aldape,Kenneth Aldape,Kenneth Aldape +83 more
TL;DR: The models developed and validated in this study provide important prognostic information not captured by previously established clinical and molecular factors which could be used to individualize decisions regarding postoperative therapeutic interventions, in particular whether to treat patients with adjuvant radiotherapy versus observation alone.
224
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma
Timothy F. Cloughesy,Joseph Landolfi,Daniel J. Hogan,Stephen Bloomfield,Bob S. Carter,Clark C. Chen,J. Bradley Elder,Steven N. Kalkanis,Santosh Kesari,Albert Lai,Ian Lee,Linda M. Liau,Tom Mikkelsen,Phioanh L. Nghiemphu,David Piccioni,Tobias Walbert,Alice Chu,Asha Das,Oscar Diago,Dawn Gammon,Harry E. Gruber,Michelle M. Hanna,Douglas J. Jolly,Noriyuki Kasahara,David McCarthy,Leah Mitchell,Derek Ostertag,Joan M. Robbins,Maria Rodriguez-Aguirre,Michael A. Vogelbaum +29 more
TL;DR: Toca 511 and Toca FC show promising results in treating recurrent high-grade glioma, and a specific molecular signature correlates with treatment-related survival, and this therapy was well tolerated and improved survival compared to an external control group.
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Timothy F. Cloughesy,Joseph Landolfi,Michael A. Vogelbaum,Derek Ostertag,James B. Elder,Stephen Bloomfield,Bob S. Carter,Clark C. Chen,Steven N. Kalkanis,Santosh Kesari,Albert Lai,Ian Lee,Linda M. Liau,Tom Mikkelsen,Phioanh L. Nghiemphu,David Piccioni,William P. Accomando,Oscar Diago,Daniel J. Hogan,Dawn Gammon,Noriyuki Kasahara,Thian Kheoh,Douglas J. Jolly,Harry E. Gruber,Asha Das,Tobias Walbert +25 more
TL;DR: Multiyear durable responses have been observed in rHGG patients treated with Toca 511 + Toca FC in a phase I trial, and the treatment will be further evaluated in a randomized phase III trial.